



## Clinical trial results:

### AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPYRESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS)

#### Summary

EudraCT number	2008-006953-41
Trial protocol	DE NL SE AT GB IT
Global end of trial date	17 October 2011

#### Results information

Result version number	v1 (current)
This version publication date	24 July 2016
First version publication date	24 July 2016

#### Trial information

##### Trial identification

Sponsor protocol code	C08-002B
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00844844
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Alexion Pharmaceuticals Incorporated
Sponsor organisation address	352 Knotter Drive, Cheshire, CT, United States, 06410
Public contact	European Clinical Trial Information, Alexion Europe SAS, +33 1 47 10 06 06, clinicaltrials.eu@alxn.com
Scientific contact	European Clinical Trial Information, Alexion Europe SAS, +33 1 47 10 06 06, clinicaltrials.eu@alxn.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 July 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	17 October 2011
Global end of trial reached?	Yes
Global end of trial date	17 October 2011
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To assess the effect of eculizumab to reduce TMA as measured by platelet count change from baseline (BL) during the Treatment Period (26 weeks) in patients with plasma therapy (PT)-resistant aHUS (protocol defined), including assessment of the proportion of patients who achieved Platelet Count Normalization from baseline through 26 weeks. Platelet Count Normalization was defined as the platelet count observed to be  $\geq 150 \times 10^9/L$  on at least two consecutive measurements which span a period of at least four weeks.

Protection of trial subjects:

Patients must have been vaccinated at least 14 days prior to receiving the first dose of eculizumab, or be vaccinated and receive treatment with appropriate antibiotics until 14 days after the vaccination.

Background therapy:

No background therapy was used in this trial.

Evidence for comparator:

Each patient served as his/her own control.

Actual start date of recruitment	24 July 2009
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	2 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	Austria: 1
Country: Number of subjects enrolled	France: 6
Country: Number of subjects enrolled	Germany: 2
Country: Number of subjects enrolled	United States: 7
Worldwide total number of subjects	17
EEA total number of subjects	10

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	1
Adults (18-64 years)	15
From 65 to 84 years	1
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Results from Study C08-002A were combined with results from another study, Study C08-002B. Study C08-002A (2008-006952-23) was conducted in adults (n=16) and Study C08-002B (2008-006953-41) was conducted in adolescents (n=1). Combined results from these 2 studies are reported here.

### Pre-assignment

Screening details:

Patients had to exhibit a decrease in platelet count despite at least 4 Plasma Therapy (PT) treatments in the 1 week immediately prior to screening. Patients who met the eligibility criteria during screening were enrolled into the Treatment Period which commenced with the first eculizumab dose.

### Pre-assignment period milestones

Number of subjects started	17
Number of subjects completed	17

### Period 1

Period 1 title	Treatment Period (26 Weeks)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Eculizumab
-----------	------------

Arm description:

All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 17 patients who were treated with study drug were included in the ITT population.

Arm type	Experimental
Investigational medicinal product name	eculizumab
Investigational medicinal product code	eculizumab
Other name	Soliris
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later.  
Maintenance dose - 1200 mg every two weeks.

Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

<b>Number of subjects in period 1</b>	Eculizumab
Started	17
Completed	15
Not completed	2
Adverse event, non-fatal	1
Protocol deviation	1

## Period 2

Period 2 title	Extension Treatment Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

<b>Arm title</b>	Eculizumab
Arm description:	
Long-term follow-up of patients receiving eculizumab	
Arm type	Experimental
Investigational medicinal product name	eculizumab
Investigational medicinal product code	eculizumab
Other name	Soliris
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later.

Maintenance dose - 1200 mg every two weeks.

Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

<b>Number of subjects in period 2<sup>[1]</sup></b>	Eculizumab
Started	13
Completed	11
Not completed	2
Adverse event, non-fatal	2

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: This extension treatment period is open to patients willing to continue to receive eculizumab until the product is registered and available. 13 patients out of the 17

that were enrolled entered this extension treatment period.

<b>Period 3</b>	
Period 3 title	Post Treatment Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded
<b>Arms</b>	
<b>Arm title</b>	Post-treatment arm
Arm description:	
Patients who discontinued eculizumab treatment at any time during the study were followed for 8 weeks after discontinuing eculizumab treatment.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Number of subjects in period 3<sup>[2]</sup></b>	Post-treatment arm
Started	6
Completed	5
Not completed	1
Consent withdrawn by subject	1

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: This period is open only to patients who discontinued eculizumab at any time during the study. 6 patients out of the 17 patients who received eculizumab discontinued treatment and entered this post-treatment period.

## Baseline characteristics

### Reporting groups

Reporting group title	Eculizumab
-----------------------	------------

Reporting group description:

All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 17 patients who were treated with study drug were included in the ITT population.

Reporting group values	Eculizumab	Total	
Number of subjects	17	17	
Age categorical			
Units: Subjects			
Adolescents (12-17 years)	1	1	
Adults (18-64 years)	15	15	
From 65-84 years	1	1	
Age continuous			
Units: years			
arithmetic mean	31.8		
standard deviation	± 13.32	-	
Gender categorical			
Units: Subjects			
Female	12	12	
Male	5	5	
Race			
Units: Subjects			
American Indian or Alaska Native	0	0	
Asian	1	1	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	1	1	
White	15	15	
More than one race	0	0	
Unknown or Not Reported	0	0	
Platelet Category			
Units: Subjects			
< 150 x10 <sup>9</sup> /L	15	15	
≥ 150 x10 <sup>9</sup> /L	2	2	
LDH category			
Units: Subjects			
> ULN	10	10	
≤ ULN	7	7	
eGFR category			
Units: Subjects			
< 15	7	7	

15 ≤ 30	5	5	
30 ≤ 45	4	4	
45 ≤ 60	1	1	
CKD Units: Subjects			
Stage 3a	1	1	
Stage 3b	4	4	
Stage 4	5	5	
Stage 5	7	7	
Platelet count Units: x10 <sup>9</sup> /L arithmetic mean standard deviation	109.03 ± 32.07	-	
LDH Units: U/L arithmetic mean standard deviation	322.5 ± 138.15	-	
Creatinine Units: micromole(s)/litre arithmetic mean standard deviation	351.5 ± 214.92	-	
eGFR Units: mL/min/1.73*m <sup>2</sup> arithmetic mean standard deviation	22.9 ± 14.54	-	



## End points

### End points reporting groups

Reporting group title	Ecuzumab
Reporting group description:	
All patients received open-label ecuzumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the ecuzumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.	
The intent-to-treat (ITT) population was defined as all patients who received any amount of ecuzumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 17 patients who were treated with study drug were included in the ITT population.	
Reporting group title	Ecuzumab
Reporting group description:	
Long-term follow-up of patients receiving ecuzumab	
Reporting group title	Post-treatment arm
Reporting group description:	
Patients who discontinued ecuzumab treatment at any time during the study were followed for 8 weeks after discontinuing ecuzumab treatment.	

### Primary: Platelet Count Change From Baseline to 26 Weeks

End point title	Platelet Count Change From Baseline to 26 Weeks <sup>[1]</sup>
End point description:	
End point type	Primary
End point timeframe:	
From Baseline to 26 weeks	
Notes:	
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: This study is a single arm trial and the system does not support statistical analyses for single arm trial.	

End point values	Ecuzumab			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: 10 <sup>9</sup> cells/L				
least squares mean (confidence interval 95%)	65.18 (37.01 to 93.36)			

### Statistical analyses

No statistical analyses for this end point

### Primary: Proportion of Patients With Platelet Count Normalization

End point title	Proportion of Patients With Platelet Count Normalization <sup>[2]</sup>
-----------------	---

---

**End point description:**

The primary objective of the study (per protocol) was to assess the effect of eculizumab to reduce TMA as measured by platelet count change from baseline (BL) during the Treatment Period (26 weeks) in patients with plasma therapy (PT)-resistant aHUS (protocol defined), including assessment of the proportion of patients who achieved Platelet Count Normalization from baseline through 26 weeks. Platelet Count Normalization was defined as the platelet count observed to be  $\geq 150 \times 10^9/L$  on at least two consecutive measurements which span a period of at least four weeks.

---

End point type	Primary
----------------	---------

---

End point timeframe:

Through 26 weeks

---

**Notes:**

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study is a single arm trial and the system does not support statistical analyses for single arm trial.

<b>End point values</b>	Eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: Percentage of Participants				
number (confidence interval 95%)	82 (57 to 96)			

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Primary: Proportion of Patients With Hematologic Normalization**

---

---

End point title	Proportion of Patients With Hematologic Normalization <sup>[3]</sup>
-----------------	--

---

**End point description:**

Hematologic Normalization was defined as normalization of both platelet count and lactic dehydrogenase (LDH) sustained for at least two consecutive measurements which spanned a period of at least four weeks.

---

End point type	Primary
----------------	---------

---

End point timeframe:

Through 26 weeks

---

**Notes:**

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study is a single arm trial and the system does not support statistical analyses for single arm trial.

<b>End point values</b>	Eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: Percentage of Participants				
number (confidence interval 95%)	76 (50 to 93)			

---

**Statistical analyses**

---

No statistical analyses for this end point

### Secondary: Proportion of Patients With Complete TMA Response

End point title	Proportion of Patients With Complete TMA Response
-----------------	---

End point description:

The proportion of patients who achieved a Complete TMA Response from baseline through 26 weeks of treatment with eculizumab was determined. Complete TMA Response was defined as Hematologic Normalization plus improvement in renal function (defined as  $\geq 25\%$  reduction from baseline in serum creatinine), which was sustained for two consecutive measurements over a period of at least four weeks.

End point type	Secondary
----------------	-----------

End point timeframe:

Through 26 weeks

End point values	Eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: Percentage of Participants				
number (confidence interval 95%)	65 (38 to 86)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: TMA Intervention Rate

End point title	TMA Intervention Rate
-----------------	-----------------------

End point description:

TMA Intervention Rate (# PE/PI and # Dialysis Events/Patient/Day) in the eculizumab treatment period (from baseline through 26 weeks) for PE/PI and (from the fifteenth day following the first eculizumab dose through 26 weeks) for new dialysis events was compared with the TMA Intervention Rate during the pre-eculizumab treatment period.

End point type	Secondary
----------------	-----------

End point timeframe:

Through 26 weeks

End point values	Eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: # events/patient/day				
arithmetic mean (standard deviation)	0.04 ( $\pm 0.1$ )			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Platelet Count Change From Baseline to 156 Weeks

End point title Platelet Count Change From Baseline to 156 Weeks

End point description:

End point type Secondary

End point timeframe:

From Baseline to 156 Weeks

<b>End point values</b>	Ecuzumab			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: 10 <sup>9</sup> cells/L				
least squares mean (confidence interval 95%)	111.62 (98.12 to 125.13)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Proportion of Patients With Platelet Count Normalization

End point title Proportion of Patients With Platelet Count Normalization

End point description:

Platelet Count Normalization was defined as the platelet count observed to be  $\geq 150 \times 10^9/L$  on at least two consecutive measurements which span a period of at least four weeks.

End point type Secondary

End point timeframe:

Through End of Study, Median Exposure 100.29 Weeks

<b>End point values</b>	Ecuzumab			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: Percentage of Participants				
number (confidence interval 95%)	88 (64 to 99)			

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Proportion of Patients With Hematologic Normalization**

---

End point title	Proportion of Patients With Hematologic Normalization
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Through End of Study, Median Exposure 100.29 Weeks

---

End point values	Eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: Percentage of Participants				
number (confidence interval 95%)	88 (64 to 99)			

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Proportion of Patients With Complete TMA Response**

---

End point title	Proportion of Patients With Complete TMA Response
-----------------	---

End point description:

The proportion of patients who achieved a Complete TMA Response from baseline through end of the study was determined. Complete TMA Response was defined as Hematologic Normalization plus improvement in renal function (defined as  $\geq 25\%$  reduction from baseline in serum creatinine), which was sustained for two consecutive measurements over a period of at least four weeks.

End point type	Secondary
----------------	-----------

End point timeframe:

Through End of Study, Median Exposure 100.29 Weeks

---

End point values	Eculizumab			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: Percentage of Participants				
number (confidence interval 95%)	76 (50 to 93)			

---

**Statistical analyses**

---

No statistical analyses for this end point

## Secondary: TMA Intervention Rate

End point title	TMA Intervention Rate
-----------------	-----------------------

End point description:

TMA Intervention Rate (# PE/PI and # Dialysis Events/Patient/Day) in the eculizumab treatment period (from baseline through end of the study) for PE/PI and (from the fifteenth day following the first eculizumab dose through end of the study) for new dialysis events was compared with the TMA Intervention Rate during the pre-eculizumab treatment period.

End point type	Secondary
----------------	-----------

End point timeframe:

Through End of Study, Median Exposure 100.29 Weeks

End point values	Ecuzumab			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: # events/patient/day				
arithmetic mean (standard deviation)	0.04 (± 0.11)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration

End point title	Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration
-----------------	--

End point description:

PK parameters C<sub>min</sub> and C<sub>max</sub> were estimated using a population PK model developed from the observed PK concentration data.

End point type	Secondary
----------------	-----------

End point timeframe:

Induction Phase for 4 weeks followed by Maintenance Phase starting on Week 5 through 26 weeks or longer

End point values	Ecuzumab			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: microgram(s)/millilitre				
arithmetic mean (standard deviation)				
max concentration during induction period	145.16 (± 26.56)			
min concentration during induction period	93.66 (± 22.1)			
max concentration during maintenance	345.14 (± 89.74)			
min concentration during maintenance	151.8 (± 68.16)			

## **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Through end of study; Exposure to eculizumab in this study extended for a median of 100 weeks and ranged from two weeks to 186 weeks.

Adverse event reporting additional description:

At every visit, patients were asked a standard non-leading question to elicit any changes in their medical well-being including inquiry about any hospitalization, accidents, and new or changed concomitant medication regimens. AEs were also documented from any data collected (e.g. laboratory values, physical examination findings, ECG changes, etc.).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.1
--------------------	------

### Reporting groups

Reporting group title	Eculizumab
-----------------------	------------

Reporting group description:

All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

Serious adverse events	Eculizumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	17 / 17 (100.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Vascular disorders			
Accelerated hypertension			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Embolism venous			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypertension			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		



Malignant hypertension			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Transplant rejection			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Alcohol withdrawal syndrome			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Respiratory fume inhalation disorder			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Bradycardia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Pericardial effusion			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Convulsion			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Headache			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Posterior reversible encephalopathy syndrome			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemolytic anaemia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemolytic uraemic syndrome			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Leukopenia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Pancytopenia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastritis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ileus			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Oesophagitis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis acute			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Renal and urinary disorders			
Haematuria			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal failure acute			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal impairment			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Systemic lupus erythematosus			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Asymptomatic bacteriuria			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Bronchitis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Escherichia sepsis			

subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Varicella			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Eculizumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	17 / 17 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Uterine leiomyoma			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Vascular disorders			
Haematoma			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Hypertension			

subjects affected / exposed	7 / 17 (41.18%)		
occurrences (all)	8		
Hypotension			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Orthostatic hypotension			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Poor venous access			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Thrombophlebitis superficial			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Surgical and medical procedures			
Tooth extraction			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences (all)	3		
Chest discomfort			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Chest pain			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Cyst			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Face oedema			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Fatigue			

subjects affected / exposed	3 / 17 (17.65%)		
occurrences (all)	3		
Influenza like illness			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Oedema			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Oedema peripheral			
subjects affected / exposed	5 / 17 (29.41%)		
occurrences (all)	5		
Pain			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences (all)	3		
Pyrexia			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences (all)	4		
Tenderness			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Thirst			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Seasonal allergy			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Reproductive system and breast disorders			
Adenomyosis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	2		
Breast calcifications			

subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Cervical dysplasia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Menorrhagia			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Metrorrhagia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	2		
Ovarian cyst			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Uterine malposition			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Vulvovaginal discomfort			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	4 / 17 (23.53%)		
occurrences (all)	4		
Dyspnoea			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Dyspnoea exertional			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Emphysema			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Epistaxis			



subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Nasal congestion			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Nasal septum deviation			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Oropharyngeal pain			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Pleural effusion			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Productive cough			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Rhinorrhoea			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Sinus congestion			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Upper-airway cough syndrome			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Psychiatric disorders			
Alcoholism			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Anxiety			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Depression			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		

Dysthymic disorder subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Insomnia subjects affected / exposed occurrences (all)	4 / 17 (23.53%) 4		
Nervousness subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Sleep disorder subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Investigations			
Antibiotic resistant Staphylococcus test positive subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 2		
Carbon dioxide abnormal subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Haematocrit decreased subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Haemoglobin decreased subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Haptoglobin decreased subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Reticulocyte count increased subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Vitamin D decreased			

subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Weight decreased			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			
Arteriovenous fistula aneurysm			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Contusion			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Excoriation			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Eye injury			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Incision site oedema			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Laceration			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Muscle rupture			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Vascular graft complication			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Cardiac disorders			
Bradycardia			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Pericardial effusion			

subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Nervous system disorders			
Ageusia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Dizziness			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences (all)	3		
Headache			
subjects affected / exposed	7 / 17 (41.18%)		
occurrences (all)	7		
Lethargy			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Loss of consciousness			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Paraesthesia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Migraine			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Presyncope			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Sinus headache			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Syncope			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		

Tremor subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	6 / 17 (35.29%) 6		
Iron deficiency anaemia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Leukopenia subjects affected / exposed occurrences (all)	3 / 17 (17.65%) 4		
Lymphopenia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Neutropenia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Ear and labyrinth disorders			
Cerumen impaction subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Vertigo subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Eye disorders			
Cataract subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Conjunctival hyperaemia			

subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Conjunctivitis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Eye pain			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Photophobia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	2		
Abdominal pain upper			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Dental caries			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Diarrhoea			
subjects affected / exposed	8 / 17 (47.06%)		
occurrences (all)	8		
Food poisoning			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Gastritis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Gastrointestinal pain			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Glossodynia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		

Haemorrhoids			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Impaired gastric emptying			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Nausea			
subjects affected / exposed	5 / 17 (29.41%)		
occurrences (all)	5		
Oral pain			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Rectal haemorrhage			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Toothache			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences (all)	3		
Vomiting			
subjects affected / exposed	8 / 17 (47.06%)		
occurrences (all)	8		
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Hepatocellular injury			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Dermatitis contact			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Dry skin			

subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Erythema			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Increased tendency to bruise			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Pruritus			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Rash			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Skin depigmentation			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Skin disorder			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Skin irritation			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Skin lesion			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Urticaria			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Haematuria			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	2		



Nephropathy toxic subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Pollakiuria subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Proteinuria subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 2		
Renal failure acute subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Renal impairment subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 5		
Renal pain subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Endocrine disorders Cushingoid subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Hyperparathyroidism secondary subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Hypothalamo-pituitary disorder subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Bone pain subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Back pain			

subjects affected / exposed	3 / 17 (17.65%)		
occurrences (all)	3		
Flank pain			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Intervertebral disc degeneration			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Joint swelling			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Muscle spasms			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Neck pain			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Myalgia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Osteopenia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Systemic lupus erythematosus			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Tendonitis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Infections and infestations			
Abscess			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		

Bronchitis			
subjects affected / exposed	4 / 17 (23.53%)		
occurrences (all)	4		
Campylobacter infection			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Cystitis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Ear infection			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Fungal infection			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Gastroenteritis			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences (all)	3		
Genital herpes			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Haemophilus infection			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Herpes zoster			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Impetigo			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Influenza			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Lower respiratory tract infection			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		

Nasopharyngitis			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences (all)	3		
Onychomycosis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Papilloma viral infection			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Pharyngitis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Pharyngitis streptococcal			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Rhinitis			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences (all)	3		
Sinusitis			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Staphylococcal infection			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Tonsillitis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Tooth abscess			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Tooth infection			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Tracheobronchitis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		

Upper respiratory tract infection subjects affected / exposed occurrences (all)	4 / 17 (23.53%) 5		
Urinary tract infection subjects affected / exposed occurrences (all)	6 / 17 (35.29%) 6		
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Metabolism and nutrition disorders			
Acidosis subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 2		
Dehydration subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Dyslipidaemia subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 2		
Fluid overload subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Fluid retention subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Hyperkalaemia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Hyperphosphataemia subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 2		
Hypocalcaemia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Hyperlipidaemia			

subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Hypokalaemia			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences (all)	3		
Hypomagnesaemia			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences (all)	2		
Iron deficiency			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Metabolic acidosis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Obesity			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Vitamin D deficiency			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 September 2009	Protocol version 2.0
26 August 2010	Protocol version 3.0

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/23738544>